Adalimumab in conjunction with surgery demonstrated more clinical effectiveness and improved quality of life in patients with hidradenitis suppurativa (HS) compared with outcomes in those treated with ...
People taking adalimumab (Humira) for moderate-to-severe hidradenitis suppurativa (HS) saw better results across the board when the drug was combined with a surgical intervention. That's according to ...
Patients with HS on adalimumab have a 53% higher risk of serious infections than those with psoriasis. HS patients are more prone to sepsis and genitourinary infections, with longer hospital stays.
The drug survival for adalimumab is significantly higher than that of infliximab in pediatric patients with hidradenitis suppurativa (HS), results from a small single-center study showed. Adalimumab ...
Exton, Pennsylvania, Jan. 10, 2024 (GLOBE NEWSWIRE) -- In late October 2023, the FDA granted approval to Novartis' Cosentyx (secukinumab) for treating hidradenitis suppurativa (HS), marking it as the ...
"Adalimumab, regardless of HiSCR responder status, was associated with improvements in common hematologic abnormalities," the authors wrote, adding that "these findings highlight the high inflammatory ...
Boil-like swellings are the hallmark of hidradenitis suppurativa (HS), a chronic, recurrent inflammatory skin disease of the hair follicle. Painful, inflamed nodules are connected via sinus tracts and ...
Yuflyma (adalimumab-aaty) and its unbranded version may now be prescribed for HS in patients 12 years and older and for UV in children 2 years and older. The Food and Drug Administration (FDA) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results